Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Other financing activities for 8 consecutive years, with $425000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other financing activities rose 53.43% year-over-year to $425000.0; the TTM value through Mar 2026 reached $1.6 million, up 5.05%, while the annual FY2025 figure was $1.5 million, 5.2% down from the prior year.
  • Other financing activities hit $425000.0 in Q1 2026 for Kymera Therapeutics, up from $416000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $641000.0 in Q3 2024 and bottomed at -$925000.0 in Q4 2023.
  • Average Other financing activities over 5 years is $276529.4, with a median of $327000.0 recorded in 2023.
  • Year-over-year, Other financing activities crashed 403.28% in 2023 and then soared 131.68% in 2024.
  • Kymera Therapeutics' Other financing activities stood at $305000.0 in 2022, then plummeted by 403.28% to -$925000.0 in 2023, then skyrocketed by 131.68% to $293000.0 in 2024, then soared by 41.98% to $416000.0 in 2025, then rose by 2.16% to $425000.0 in 2026.
  • According to Business Quant data, Other financing activities over the past three periods came in at $425000.0, $416000.0, and $419000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.